Peptibase
Weight Loss

Setmelanotide

Also known as: Imcivree, RM-493

FDA Approved
Share:

Popular For

Genetic obesity disorders, rare metabolic conditions

Key Facts: Setmelanotide

Category
Weight Loss
FDA Status
FDA Approved
Clinical Status
FDA Approved - Specific genetic obesities
Administration
Subcutaneous injection daily
Typical Dose
2-3 mg daily
Frequency
Once daily
Evidence Level
FDA Approved
Duration
Long-term / chronic use
Also Known As
Imcivree, RM-493

Mechanism of Action

Setmelanotide activates melanocortin-4 receptors (MC4R) in the hypothalamus, restoring the satiety signaling pathway that is disrupted in certain genetic obesity syndromes. Works downstream of leptin signaling.

Research Summary

Approved for POMC, PCSK1, and LEPR deficiency obesity. Studies show significant weight loss in these specific populations where other treatments fail. Precision medicine approach.

Clinical Status:FDA Approved - Specific genetic obesities
Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical Dosingⓘ

Community experience

Common Dose

2-3 mg daily

Range

1-3 mg daily

Frequency

Once daily

FDA-approved for specific genetic obesities (POMC, PCSK1, LEPR deficiency). Prescription only.

Research Dosingⓘ

Scientific studies

FDA-approved dosing

Doses from Studies

Weight-based dosing (pediatric)

FDA Approved Labeling - Prescribed dose ↗

Duration

Long-term / chronic use

Administration

Subcutaneous injection daily

Timing & Administration

Best Time to Take

Before bed or morning (fasted)

Follow specific peptide protocol

Food Recommendation

Take on empty stomach

Why This Timing?

GH-related peptides work best on an empty stomach to maximize growth hormone release.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●Skin hyperpigmentation (67-83%)
  • ●Injection site reactions
  • ●Nausea
  • ●Spontaneous erections in males
  • ●Priapism risk
  • ●Depression risk
  • ●FDA approved (Imcivree)

References

Related Peptides

Peptides commonly compared with Setmelanotide or used in similar applications.

Semaglutide

FDA

A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.

Weight Loss

Tirzepatide

FDA

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.

Weight Loss

Liraglutide

FDA

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.

Weight Loss

Dulaglutide

FDA

An FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.

Weight Loss

Exenatide

FDA

The first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. Available in twice-daily and weekly formulations.

Weight Loss

Semaglutide Oral

FDA

The oral formulation of semaglutide using SNAC absorption enhancer. First oral GLP-1 receptor agonist FDA approved.

Weight Loss
How to Use SetmelanotideSetmelanotide AlternativesCompare with SimilarBrowse All Peptides

Looking for a trusted vendor?

Pro members get access to verified vendors with quality standards & exclusive discount codes.

View Verified Vendors
PRO

Want updates on Setmelanotide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides